Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

TD2 Allies With Horizon Discovery

April 12, 2010 6:00 am | News | Comments

A strategic alliance between TGen Drug Development (TD2) and Horizon Discovery Limited will significantly advance personalized medicine.


Partnership to Explore mCRC Biomarkers

April 12, 2010 5:54 am | News | Comments

Almac, Merck KGaA, and the Medical Research Council, have partnered to undertake a study to assess potential biomarkers of response to cetuximab (Erbitux) using samples from the MRC COIN trial.


Study Finds Link Between Stress, Anxiety, And Depression

April 12, 2010 5:47 am | News | Comments

The study also reveals a small molecule inhibitor developed by Ferguson, which may provide a new and better way to treat anxiety, depression and other related disorders


Faulty Clean-Up May Be Behind Huntington's

April 12, 2010 5:44 am | News | Comments

In a step towards a possible treatment for Huntington's disease, scientists at Albert Einstein College of Medicine of Yeshiva University have shown for the first time that the accumulation of a mutated protein may explain damaging cellular behavior in Huntington's disease.


Study Reveals Biology of Vancomycin Resistance

April 12, 2010 5:39 am | News | Comments

A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.


Key Protein Aids In DNA Repair

April 12, 2010 5:35 am | News | Comments

Scientists have shown in multiple contexts that DNA damage over our lifetimes is a key mechanism behind the development of cancer and other age-related diseases.


Study of Protein Architecture May Aid Drug Design

April 12, 2010 5:32 am | News | Comments

Researchers in Singapore are reporting this week that they have gleaned key insights into the architecture of a protein that controls iron levels in almost all organisms.


Researchers Photograph Highly Dynamic Proteins

April 12, 2010 5:28 am | News | Comments

Researchers at IRB Barcelona have refined the process of obtaining "photographs" of highly dynamic proteins, an important step in drug design.


Clinical Trial Management

April 9, 2010 6:53 am | Product Releases | Comments

BioClinica, Inc., a global provider of clinical trial management services, has released BioClinica WebSend, a system that simplifies and accelerates image collection for clinical studies.


Flow Cells

April 9, 2010 6:48 am | Product Releases | Comments

Through an in-depth understanding and innovative exploitation of material properties that are important for micro-scale experimentation, Dolomite has developed and manufactured a range of standard and customized flow cells for chemical analysis.


Abbott Offers to Buy Facet Biotech for $450M

April 9, 2010 6:41 am | News | Comments

Abbott announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to Abbott's cash tender offer to purchase all of the outstanding shares of common stock of Facet Biotech Corporation has expired, satisfying one of the conditions necessary for the consummation of the tender offer.


Charles Bancroft Elected CFO of BMS

April 9, 2010 6:26 am | News | Comments

Bristol-Myers Squibb Company announced that the Board of Directors has elected Charles Bancroft chief financial officer.


Tioga Reaches Agreement With FDA on IBS Drug

April 9, 2010 6:20 am | News | Comments

Tioga Pharmaceuticals, Inc. has reached an agreement with the FDA on Special Protocol Assessments (SPAs) for the Phase 3 efficacy protocols for asimadoline for patients with D-IBS.


Daiichi Sankyo Submits Edoxaban NDA

April 9, 2010 6:13 am | News | Comments

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to in Japan seeking approval of the anticoagulant, edoxaban, for the prevention of venous thromboembolism (VTE) after major orthopedic surgery.


Peptide Allows Deeper Tumor Penetration

April 9, 2010 6:07 am | News | Comments

Researchers have shown that a peptide called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate, and pancreatic cancers in mice.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.